480 STUDY: Phase 2b Study of Locteron Plus Ribavirin to Treat Hepatitis C Virus (HCV)

PHASE2CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

May 31, 2010

Study Completion Date

January 31, 2011

Conditions
Hepatitis C, Chronic
Interventions
DRUG

ribavirin

Ribavirin - oral administration Subjects with body weight \< 65 kg: 800 mg/day Subjects with body weight 65-85 kg: 1000 mg/day Subjects with body weight 86-105 kg: 1200 mg/day Subjects with body weight \> 105 kg: 1400 mg/day

Trial Locations (15)

1407

Tokuda Hospital, Sofia

1431

"UMHAT Alexandrovska", Sofia

"UMHAT St Ivan Rilski", Sofia

1527

"UMHAT Queen Giovanna - ISUL EAD", Sofia

1606

Medical Institute Ministry of Interior, Sofia

9010

"UMHAT St Maria", Varna

13100

Rebekah Ziv Medical Center Safed, Safed

16100

Holy Family Hospital Nazareth, Nazareth

34341

Carmel Medical Center, Haifa

49100

Rabin Medical Center, Petah Tikva

64239

Sourasky Medical Center, Tel Aviv

200515

"Victor Babes Clinical Hospital Craiova", Craiova

700111

Gastroenterology and Hepatology Institute, Iași

021105

Institute of Infectious Diseases, Bucharest

022328

Fundeni Clinical Institute, Bucharest

Sponsors
All Listed Sponsors
lead

Biolex Therapeutics, Inc.

INDUSTRY